Volume No. :   5

Issue No. :  2

Year :  2013

ISSN Print :  0975-234X

ISSN Online :  0975-4377


Registration

Allready Registrered
Click to Login

A Novel visible spectrophotometric method development for the estimation of oseltamivir phosphate in capsules based on ferric hydroxamate reaction



Address:   B. Kalyana Ramu2*, M. Syam Bab1, U. Viplava Prasad1
1Department of Organic Chemistry& Analysis of Foods Drugs &water Laboratories, School of Chemistry, Andhra University, Visakhapatnam-530003 Andhra Pradesh (India)
2Department of Chemistry, Maharajah’s College (Aided& Autonomous), Vizianagaram-535002 (AP) India.
*Corresponding Author:
DOI No:

ABSTRACT:
A Simple, sensitive spectrophotometric method in visible region was developed for the estimation of osetamivir phosphate in bulk and solid dosage forms. The method is based on the ferric hydroxamate reaction purple red colored species is formed with hydroxylamine-ferric per chlorate reagent in non aqueous medium which exhibits maximum absorption at 514 nm. Beer’s law obeyed in the concentration range of 20-60µg/ml. commercially available Natflu capsules were analyzed, and the results are statistically compared with those obtained by the UV reference method and validated by recovery studies. The results obtained by the proposed method were in good agreement with the labeled amounts and found satisfactory and reproducible. The method is applied successfully for the estimation of the Oseltamivir phosphate in the presence of other ingredients that are usually present in dosage forms. The method offers the advantages of rapidity, simplicity and sensitivity and normal cost and can be easily applied to resource-poor settings without the need for expensive instrumentation and reagents.
KEYWORDS:
Anti viral, capsules, Hydroxylamine, Ferric per chlorate, Regression equation
Cite:
B. Kalyana Ramu, M. Syam Bab, U. Viplava Prasad. A Novel visible spectrophotometric method development for the estimation of oseltamivir phosphate in capsules based on ferric hydroxamate reaction. Research J. Pharma. Dosage Forms and Tech. 2013; 5(2): 70-74
[View HTML]      [View PDF]



Visitor's No. :   144831